drugset / Trial / NCT00940160

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients

NCT00940160

Phase 1/2 Completed 30 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to investigate the safety and tolerability of multiple doses of QAX576 in controlled or partially controlled asthma patients.

Timeline

Start
2009-07
Primary completion
2010-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator QAX576 Monoclonal antibody 1 mg/kg Intravenous
Comparator QAX576 Monoclonal antibody 3 mg/kg Intravenous
Comparator QAX576 Monoclonal antibody 10 mg/kg Intravenous

Indications